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Abstract: Data from Continuous Glucose Monitoring (CGM) systems may help improve 
overall daily glycemia; however, the accuracy of CGM during exercise remains 
questionable. The objective of this single group experimental study was to compare  
CGM-estimated values to venous plasma glucose (VPG) and capillary plasma glucose 
(CPG) during steady-state exercise. Twelve recreationally active females without diabetes 
(aged 21.8 ± 2.4 years), from Central Washington University completed the study. CGM is 
used by individuals with diabetes, however the purpose of this study was to first validate 
the use of this device during exercise for anyone. Data were collected between November 
2009 and April 2010. Participants performed two identical 45-min steady-state cycling 
trials (~60% Pmax) on non-consecutive days. Glucose concentrations (CGM-estimated, 
VPG, and CPG values) were measured every 5 min. Two carbohydrate gel supplements 
along with 360 mL of water were consumed 15 min into exercise. A product-moment 
correlation was used to assess the relationship and a Bland-Altman analysis determined 
error between the three glucose measurement methods. It was found that the CGM system 
overestimated mean VPG (mean absolute difference 17.4 mg/dL (0.97 mmol/L)) and mean 
CPG (mean absolute difference 15.5 mg/dL (0.86 mmol/L)). Bland-Altman analysis 
displayed wide limits of agreement (95% confidence interval) of 44.3 mg/dL (2.46 mmol/L) 
(VPG compared with CGM) and 41.2 mg/dL (2.29 mmol/L) (CPG compared with CGM). 
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Results from the current study support that data from CGM did not meet accuracy 
standards from the 15197 International Organization for Standardization (ISO). 
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1. Introduction 
Maintaining glycemic control and avoiding hypo- and hyperglycemia during and after exercise can 
be challenging for physically active individuals with type 1 diabetes [1]. In addition to those 
performing regular physical activity, an increased number of individuals with diabetes are participating 
in endurance events [2]. Prolonged or strenuous exercise may increase the risk for hypoglycemia for 
up to 24 h after exercise; often requiring more extensive blood glucose monitoring to prevent nighttime 
hypoglycemia [3–7].  
Continuous Glucose Monitoring (CGM) systems can provide continuous glucose concentrations to 
individuals with diabetes. The majority of CGM systems estimate glucose concentrations by measuring 
interstitial fluid glucose (IFG) and can be worn for 3 to 7 days at a time [8]. With the Dexcom  
(San Diego, CA) SEVEN PLUS, a small platinum wire (sensor) is inserted into the subcutaneous 
tissue of the abdominal region (DexCom specific) and IFG is measured continuously via a glucose 
oxidase reaction [8,9]. The receiver records the average glucose concentration every 5 min and stores 
glucose trend reports [8]. CGM-generated continuous glucose values and glucose rate of change 
information may be beneficial for physically active individuals with diabetes [2,5,10]. 
The use of CGM has been reported to improve long-term glycemic management, without increasing 
hypoglycemic episodes [11–16]. Some studies have used CGM to evaluate glucose profiles before and 
after exercise [2,17,18]. However, the reliability of individual values from CGM when blood glucose 
is changing rapidly remains controversial [19–21]. Because individuals may benefit from the 
convenience of fewer finger sticks, it is important to compare CGM to other blood glucose 
measurement methods during and after exercise. Although these devices were developed for 
individuals with diabetes, it is important to validate their use during exercise for those without diabetes 
to document ―normal‖ responses for future comparative studies. The purpose of this study was to 
compare the DexCom SEVEN
®
 PLUS CGM system (IFG) to venous plasma glucose (VPG) and 
capillary plasma glucose (CPG) measurements during exercise and recovery in individuals without 
diabetes to estimate its value as a training or research tool. The study hypothesized that the difference 
between CGM and VPG (reference method), as well as CPG would suggest acceptable agreement 
between methods during moderate exercise. 
2. Experimental Section  
2.1. Study Population 
Volunteers were recruited over a 5-month period through class announcements and flyers at Central 
Washington University (CWU) by the lead investigators. Enrollment criteria included: age between  
18 and 44 years, non-pregnant, absence of diabetes diagnosis or hypoglycemic episodes, recreationally 
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active individuals (≥20 min of moderate-intensity aerobic exercise, ≥three times per week) [22], and a 
―low risk‖ health status based on the American College of Sports Medicine [23]. Health status was 
assessed with a medical health history questionnaire. All study procedures were approved by the CWU 
Human Subjects Review Committee and written informed consent was given by all participants. 
2.2. Experimental Design 
The single group experimental design required participants to wear a SEVEN
®
 PLUS CGM system 
for 6 to 7 continuous days and perform the following three exercise sessions: peak oxygen 
consumption (VO2peak) and two identical steady-state cycling trials. Participants abstained from 
caffeine, alcohol, and strenuous exercise for ≥24 h prior to day 1, and ≥8 h before subsequent cycling 
sessions; otherwise, diet was not controlled in this study. Participants were assessed for descriptive 
data: age (years), height (cm), weight (kg), and body mass index (BMI; calculated as kg/m
2
). Body fat 
percentage was estimated by a trained investigator with Lange skinfold calipers (Cambridge, MD) 
using a three-site method (tricep, suprailiac, thigh) [24] and Siri equation [23]. The SEVEN
®
 PLUS 
sensor was inserted just under the skin of the abdominal tissue by a DexCom-trained investigator on 
day 1, and remained in place until completion of the study. Participants were instructed to enter 2 CPG 
values into the CGM device at initiation to calibrate the device, then 1 CPG value whenever the device 
requested for further calibration purposes. The CGM adjusts based on the CPG glucose values, but 
continues to display IFG. 
VO2peak Protocol (Day 1) 
VO2peak was estimated during an incremental exercise test to volitional exhaustion on a cycle 
ergometer to determine exercise intensity for submaximal trials. Gas exchange was measured using a 
two-way breathing valve (Hans Rudolph, Kansas City, MO) attached to a metabolic measurement 
system (Parvo Medics’ TrueOne
®
 2400, UT). Heart rate (Polar electro OY, Polar, Stamford, CT) and 
rating of perceived exertion (RPE), using a Borg 6- to 20-point scale [25], was recorded every minute. 
After a 2-min warm-up, the resistance was increased by 0.5 kilopond every 2 min for the first 4 min; 
after which resistance increased every minute until the individual reached volitional exhaustion 
(VO2peak) [26]. Participants’ peak power outputs (Pmax) were defined as the maximum resistance 
achieved at volitional exhaustion [23]. 
2.3. Steady-State Cycling Sessions 
Participants arrived in a fasted state (≥8 h) at 6:30 a.m. on days 2 and 4. Following baseline blood 
glucose collection, participants completed a 5-min warm-up. Participants then cycled at a workload 
corresponding to ~60% Pmax for 45 min, while maintaining a cadence of 60 revolutions per minute. 
Fifteen min into the cycling trial, participants ingested two PowerBar (Glendale, CA) gel supplements 
(each containing 110 kcals, 27 g carbohydrate, 0 g protein, 0 g fat, 200 mg sodium, 20 mg potassium, 
and 10 g sugar) along with 360 mL of water within 5 min.  
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2.4. Measurements during Steady-State Cycling Tests 
Blood glucose was measured at baseline, every 5 min during exercise and for 15 min after exercise, 
using three techniques: venous blood sampling through an indwelling catheter, capillary blood draw, 
and interstitial fluid using CGM. During each trial, a total of 13 samples were collected from  
each method. 
VPG was used as the reference method in this study. A sterile, over-the-needle catheter was used 
for serial blood sampling during exercise. The catheter was cannulated into an arm vein by a trained 
technician and its patency was maintained with a standard saline lock technique. Venous blood was 
drawn into heparinized vacutainers (4 mL) and immediately placed on ice. Samples were then 
separated with a refrigerated centrifuge for 10 min (Precision Durafuge 200R, Thermo Scientific, 
Waltham, MA). Glucose concentrations were measured using a glucose oxidase colorimetric assay 
(Pointe Scientific Inc, Canton, MI) measured at absorption of 540 nm with an UV-Visible Recording 
Spectrophotometer UV-160U (Shimadzu Corp, Kyoto, Japan). The average absorbance of triplicate 
samples was used for comparison unless outliers existed. Individual absorbance values >10% from the 
mean at that time point were considered outliers and excluded from the average. 
CPG was measured via finger sticks with an Ascensia Contour glucometer (Bayer Healthcare LLC, 
Mishawaka, IN). The SEVEN
®
 PLUS estimated blood glucose via a glucose oxidase reaction, and 
reported an average every 5 min [8,9]. Participants were instructed to calibrate the CGM system with a 
CPG value every 12 h and additionally if indicated by the CGM receiver. 
2.5. Statistical Analysis 
Based on data from previous research, to achieve a power of 0.80, based on a mean glucose of  
100 mg/dL and an estimated effect size of 1.0 standard deviation (~20 mg/dL), at least 10 participants 
were needed for this study [5,18,27]. Descriptive characteristics (mean ± standard deviation) were 
computed. Blood glucose data from the two submaximal trials were analyzed individually to examine 
agreement between blood glucose measurement devices. Absolute differences for glucose values were 
determined at each time point between glucose measurement methods, and mean differences 
calculated. Product-moment correlation coefficients were used to assess the relationship between 
methods. A Bland-Altman analysis was used for error analysis to determine the agreement between 
CGM-estimated, VPG, and CPG values [28], by computing the differences between values from each 
measurement method at each time point and plotting it against the average of the 2 devices. Statistical 
analyses were performed using Microsoft Excel (Microsoft Corporation 2007, Redmond, WA) and 
SPSS 16.0 (2007, Chicago, IL), with statistical significance set at P ≤ 0.05. 
3. Results  
3.1. Participant Characteristics 
Twelve female participants without diabetes completed the study. Participants were 21.8 ± 2.4 years 
of age, normal weight (BMI 22.8 ± 2.3), 20.7% ± 4.3% body fat, and had a VO2peak of  
39.7 ± 4.0 mL/kg/min. 
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3.2. Blood Glucose Analysis 
Figure 1 displays the average glucose values for each device during the submaximal exercise. There 
was a 17.4 mg/dL and 15.5 mg/dL mean absolute difference between VPG and CGM-estimated values 
and between CPG and CGM-estimated values, respectively. On average, there was a tendency for 
CGM to overestimate VPG. In addition, mean absolute difference of 11.6 mg/dL was identified 
between VPG and CPG values. 
Figure 1. Effect of exercise and carbohydrate supplementation on glucose response during 
45 min of steady-state moderate-intensity cycling and 15 min of recovery, performed by 
healthy females in a study to determine the comparability of three glucose monitoring 
methods. Average glucose values for each measurement method taken at 5 min intervals. 
VPG = Venous plasma glucose, CGM = Continuous glucose monitoring; CPG = Capillary 
plasma glucose. 
 
There was moderate positive correlation between VPG and CGM-estimated glucose values for 271 
paired samples (r = 0.6, P < 0.05). Similar findings were found between CPG and CGM-estimated 
glucose values for 285 paired samples (r = 0.6, P < 0.05). Bland-Altman analysis suggested 
unsatisfactory agreement between VPG and CGM-estimated values (r = 0.5; mean difference  
4.0 ± 22.6 mg/dL; 0.22 ± 1.25 mmol/L) (Figure 2) and between CPG and CGM-estimated values  
(r = 0.4; mean difference 3.0 ± 21.0 mg/dL; 0.17 ± 1.17 mmol/L). See Figure 2 for similar 
representation of CPG compared to CGM-estimated values.  
Nutrients 2012, 4  
 
 
1287 
Figure 2. Limits of agreement between venous plasma glucose and continuous glucose 
monitoring-estimated values during 45 min of steady-state moderate-intensity cycling and 
15 min of recovery (r = 0.5) performed by healthy females in a study to determine the 
comparability of three glucose monitoring methods. 4.4% of values outside the limits of 
agreement fell above the upper limit. 
 
The 95% limits of agreement were defined as 2 standard deviations from the glucose mean 
difference (1.96 times standard deviation) [28]. The limits of agreement were ±44.3 mg/dL  
(2.46 mmol/L) for VPG vs. CGM-estimated values and ±41.2 mg/dL (2.29 mmol/L) for CPG vs. 
CGM-estimated values. The limits of agreement between each of these methods tended to increase as 
average glucose increased. When the steady-state cycling trials were broken into stages, the increase in 
mean difference and limits of agreement were identified as follows for VPG compared to CGM values: 
baseline (mean difference ± 2 standard deviations) 1.7 ± 25.1 mg/dL (0.09 ± 1.40 mmol/L), exercise 
only (5–15 min) 0.8 ± 26.5 mg/dL (0.04 ± 1.47 mmol/L), exercise plus carbohydrate (20–45 min)  
2.1 ± 47.8 mg/dL (0.12 ± 2.65 mmol/L), and post-exercise (50–60 min) 11.4 ± 53.7 mg/dL  
(0.63 ± 2.98 mmol/L). A similar trend was found when comparing CPG to CGM values: baseline  
1.3 ± 21.3 mg/dL (0.07 ± 1.18 mmol/L), exercise only (5–15 min) 1.7 ± 22.9 mg/dL (0.09 ± 1.27 mmol/L), 
exercise plus carbohydrate (20–45 min) 2.0 ± 48.1 mg/dL (0.11 ± 2.67 mmol/L), and post-exercise 
(50–60 min) 6.8 ± 45.1 mg/dL (0.38 ± 2.50 mmol/L). 
Results from the current study did not meet the International Organization for Standardization 
15197 (ISO) standards for accuracy [29,30]. Using glucometers, 95% of values ≥75 mg/dL  
(4.2 mmol/L) should be within ±20% of the blood glucose concentration, and within ±15 mg/dL  
(0.83 mmol/L) for values <75 mg/dL (4.2 mmol/L), to be considered acceptable [29,30]. Only 69.4% 
and 72.7% of CGM-estimated values ≥75 mg/dL (4.2 mmol/L)) were within the ISO 15197 standards 
when compared to VPG and CPG, respectively. For CGM-estimated values <75 mg/dL (4.2 mmol/L) 
only 27.6% and 51.7% met these standards when compared to VPG and CPG, respectively. 
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4. Discussion  
The purpose of the current study was to examine the acceptability of using a CGM system to 
estimate blood glucose during exercise with a carbohydrate feeding. CGM systems were developed to 
help improve daily glycemic control and prevent detrimental episodes of hypo- or hyperglycemia. The 
validation of CGM devices in the diabetes population, as an adjunct for improving daily glycemic 
control is well documented [11–16]; however limited research regarding their acceptability for use 
during exercise and in those without diabetes remains questionable [2,5,10,17,20,27]. An athlete’s 
blood glucose during exercise has the potential to increase/decrease rapidly and can be difficult to 
monitor. The interference of self-monitoring of blood glucose, or finger stick, testing during intense 
training or competition may disturb an athletes’ performance [6,20]. For individuals with diabetes, 
hypo- and hyperglycemia are common after strenuous endurance events, lasting up to 24 h [3,7]. 
Therefore, CGM may be beneficial for athletes because CGM provides continuous readings and 
glucose rate of change information that warns individuals about rapidly increasing or decreasing 
glucose profiles. Despite the limited studies examining the point-accuracy of CGM systems (available 
in the US) during exercise, CGM has been shown to be useful during exercise by helping athletes 
understand personal glycemic profiles during and after activity [2,5,10,17]. 
Similar to other research findings [5,18,27], the current study found a large potential variable 
difference between CGM-estimated and VPG, as well as CPG values during exercise. In contrast, some 
studies report an overall acceptable agreement between measures (CGM, venous, and capillary) [18,27]. 
Results from the current study revealed absolute mean differences similar to other findings using the 
DexCom SEVEN
®
 in non-exercise studies (12.8% to 16.3% mean absolute relative differences) [31,32]. 
The correlation between CGM values and blood glucose in the current study was lower than found 
in previous studies (r = 0.8 to 0.9) [5,27]. Similar results have been reported when comparing CGM 
values to either CPG or VPG values [5,33]. Discrepancy in this difference might be related to a smaller 
blood glucose range in the current study compared to previous research with individuals with diabetes. 
In contrast to the current study, other researchers have reported satisfactory agreement between VPG 
and CGM-estimated values during exercise, using Bland-Altman analysis [18,27], despite having 
larger mean differences. 
Under moderate-intensity cycling, resting, and recovery conditions in the current study, CGM on 
average, had a tendency to overestimate mean VPG. Similarly, MacDonald et al. [18] reported a 
tendency of overestimation by another CGM system, during moderate-intensity exercise. Furthermore, 
the consistency of the differences between the methods increased in concordance with average  
glucose [18]. However, Fayolle et al. [27] reported an average overestimation with the GlucoDay
®
  
(A. Menarini Diagnostics, Florence, Italy) during low-intensity exercise (mean difference  
16.4 ± 4.1 mg/dL, P < 0.0001); with a tendency to underestimate VPG during high-intensity exercise 
(−25.9 ± 11.0 mg/dL). Some literature suggests that IFG may decrease more rapidly than blood 
glucose during exercise because of the rapid uptake of glucose by the muscles [17]. However, in the 
current study, average CGM values tended to overestimate VPG during exercise and recovery. In 
addition, IFG via CGM was measured in adipose tissue of the abdominal region, not in the exercising 
muscle. Nevertheless, it has been proposed that IFG differs insignificantly between body 
compartments [34]. This can present as a confounding variable because of the potential differences 
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between glucose uptake in interstitial fluid surrounding muscles and adipose tissue. Due to the nature 
of this study, it is likely that a physiological lag-time between these compartments might have 
contributed to differences found in the study. 
Since CPG is the standard measure for individuals with diabetes during normal daily activities, we 
examined whether CGM is acceptable compared to CPG. Several others support this in their research 
by using CPG; although, most often using VPG as their standard during exercise and non-exercise 
states [5,33,35,36]. In contrast to at least one study [37], the current study reported that CGM 
overestimated CPG on average. Few studies during exercise have examined the accuracy between 
CGM and CPG values. Of these studies, Iscoe et al. [5] identified a strong correlation (r = 0.89,  
P < 0.001) between these two methods during exercise. However, Wilhelm et al. [35] reported no 
significant differences between CPG and CGM values during non-exercise states. 
Although Bland-Altman plots identified some agreement between blood glucose methods, these 
results did not meet the ISO standards [29,30]. When analyzed by stage, the limits of agreement 
between CGM and VPG values and between CGM and CPG values increased as the exercise 
progressed. One exception was found between CPG and CGM values during recovery. Therefore, 
under the current study conditions, the CGM system appeared to be more acceptable at the beginning 
of exercise, possibly because fewer variables were imposed on the participant, and the rate of glucose 
change was negligible, whereas blood glucose increased rapidly later during exercise [32]. To our 
knowledge, current research has not examined the addition of carbohydrate feeding during exercise on 
CGM acceptability. 
This study was not without limitations. Because glucometers may have acceptable deviation of 
±20%, the accuracy of relying on a single CPG measure at each time point, as done in the current 
study, may not be an accurate comparison in such a research study. Averages of triplicate 
measurements might yield more accurate results for CPG. 
It has been proposed that CGM may not be as accurate or effective in individuals without diabetes 
because of narrow daily glucose ranges [5,18]. McGowan et al. [33] reported weaker correlations in 
participants with diabetes with the tightest daily blood glucose ranges, suggesting that narrower 
glucose profiles may result in greater variance of CGM [33]. However, other studies using CGM in 
healthy populations without diabetes report similar variance between CGM-estimated and VPG values, 
as well as with CPG compared to individuals with diabetes [18,21]. Mean differences in the current 
study were smaller than reported by MacDonald et al. [18], however both suggested similar 
overestimations of blood glucose by CGM. Although the range of blood glucose concentrations in 
individuals without diabetes is more limited, the present results shed light on differences in accuracy in 
methods for measuring blood glucose, regardless of whether individuals have diabetes. These results 
can be used as ―reference values‖ in individuals without diabetes for future comparative studies. 
Although MacDonald et al. [18] reported similar variance to the present study, based on results from 
McGowan et al. [33], we suggest CGM devices may be suitable for individuals with diabetes to use 
during exercise. Future comparative studies involving CGM devices, exercise and individuals with 
diabetes would help to confirm this notion. 
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5. Conclusions  
In conclusion, based on the results of the current study, CGM was not found to consistently provide 
acceptably accurate glucose values when compared to VPG or CPG during moderate-intensity cycling 
and recovery. These results provide information on the accuracy of CGM during exercise, but cannot 
be directly translated to non-exercise conditions. Therefore, CGM should be used in conjunction with 
standard glucometers during and after exercise to improve accuracy and confirm extreme values before 
taking corrective action. Further research is warranted to examine the acceptability of CGM during 
exercise in individuals with and without diabetes.  
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